{"id":"W2980850490","doi":"10.1200/po.19.00221","title":"Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Sanofi; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Fibroblast growth factor receptor 1; Tolerability; Medicine; Fibroblast growth factor receptor; Cancer; Breast cancer; Oncology; Internal medicine; Cancer research; Pharmacology; Receptor; Adverse effect; Fibroblast growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002519108,0.0002912787,0.000446093,0.0001848919,0.0001027726,0.00007026433,0.0001197445,0.0002309975,0.00007119957],"category_scores_gemma":[0.00008898279,0.0001831979,0.00001897005,0.0002382886,0.0002369751,0.00004030939,0.0001909254,0.0002895447,0.00001147048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006314149,"about_ca_system_score_gemma":0.0003512251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004983372,"about_ca_topic_score_gemma":0.001338049,"domain_scores_codex":[0.9980004,0.0002090731,0.0003629301,0.0006835363,0.0003420418,0.0004020491],"domain_scores_gemma":[0.9988789,0.00011381,0.0001813984,0.0003897457,0.0002591179,0.0001770297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01924335,0.0006194441,0.8879141,0.00007924239,0.00008266364,0.00003702232,0.0005031982,0.0001190921,0.08667902,0.00006312714,0.0004535986,0.004206179],"study_design_scores_gemma":[0.03246044,0.07455087,0.8262172,0.0006876681,0.00005480141,0.0002072387,0.0004547154,0.001041635,0.0572985,0.00008648108,0.00591399,0.001026478],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975107,0.00003088848,0.0002620381,0.0002149057,0.00003715745,0.001363507,0.00003798545,0.00001720017,0.0005256736],"genre_scores_gemma":[0.9972256,0.00003477624,0.001825804,0.0001890001,0.00003667987,0.0000967575,0.0002482546,0.00004641564,0.0002967303],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07393143,"threshold_uncertainty_score":0.7470592,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007405147188545542,"score_gpt":0.2759090181197813,"score_spread":0.2685038709312357,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}